Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
4 participants
OBSERVATIONAL
2021-06-10
2024-08-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pneumonia Vaccine in Liver Transplant Recipients: a Booster Strategy Using a Conjugate Vaccine
NCT00152802
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
NCT00980655
Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of Donor Vaccination
NCT00143780
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
NCT07135453
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
NCT05489328
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will not accrue benefits personally. However, participation will help others by identifying whether current vaccination strategies in this population are adequate.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PCV15 only
Draw blood for ELISA and OPA, then administer PCV15
PCV15
Blood draw after the vaccination
PPS23 only
Draw blood for ELISA and OPA, then administer PPS23
No interventions assigned to this group
PCV15 and PPS23
Draw blood for Administer PPS23 then draw blood again ELISA and OPA, then administer PCV15
PCV15
Blood draw after the vaccination
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PCV15
Blood draw after the vaccination
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Either undergoing evaluation for heart transplant (with or without LVAD receipt), or having received a heart transplant
* Receiving a dose of PCV15 or PPSV23 (or both sequentially) concordant with AST guidelines
Exclusion Criteria
* Subjects without the capacity to consent
* Pregnancy
* Already up to date on pneumococcal vaccination or declining vaccination
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Sunfire Biotechnologies
UNKNOWN
Quest Clinical Research
OTHER
Montefiore Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vagish Hemmige, MD
Role: PRINCIPAL_INVESTIGATOR
Montefiore Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Montefiore Medical Center, Infectious Diseases
The Bronx, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MISP 60528
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2021-12637
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.